) Monitoring gene expression patterns using microarrayed grids of eDNA fragments is a powerful new tool for analyzing tumors. An in-house capacity to design and prepare microarrays will give us the opportunity to tailor the design of low-cost gene chips to the needs of the melanoma program project. Expensive commercial chips (which presently contain >15,000 eDNAs per grid and are expected to soon include cDNAs representing most or all expressed human genes) can be purchased and used sparingly for very selected experiments, and interesting cDNA clones identified from the results of these """"""""global"""""""" experiments can he selected for inclusion on the smaller, cheaper, and more readily available core-generated microarrays. These novel microarray design strategies will avoid the huge expense likely to be incurred by the routine use of commercial gene chips, and will facilitate data interpretation by simplifying the quantitative gene expression readout to a limited (but still very large) set of eDNAs known to or expected to fluctuate in interesting ways in melanoma. Microarrays will be used extensively for 3 of the 4 projects. Core E will interact closely with the proteome analysis component of Core D in order to facilitate the design of custom microarrays for some of the projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA025874-23
Application #
6594579
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-01
Project End
2003-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2002
Total Cost
$312,755
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Heppt, Markus V; Wang, Joshua X; Hristova, Denitsa M et al. (2018) MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. J Invest Dermatol 138:141-149
Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Krepler, Clemens; Sproesser, Katrin; Brafford, Patricia et al. (2017) A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21:1953-1967
Somasundaram, Rajasekharan; Zhang, Gao; Fukunaga-Kalabis, Mizuho et al. (2017) Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8:607

Showing the most recent 10 out of 382 publications